Multiple Sclerosis, Rituximab, Hypogammaglobu...

In part two of this two-part series, recorded at this year's AAN Annual Meeting, Dr. Gregg Day talks with Drs. Joel Salinas and Sarah Song about imperfect but practical brain health metrics, patient-centered assessment strategies, and future directions in brain health assessment. ...  Show more

In part one of this two-part series, recorded at this year's AAN Annual Meeting, Dr. Gregg Day talks with Drs. Joel Salinas and Sarah Song about the evolving landscape of brain health, practical approaches to incorporating brain health assessments into routine care, and the impor ...  Show more

Dr. Shuvro Roy and Dr. Annette Langer-Gould discuss the effective dose of rituximab and other B-cell depleting therapies in patients with multiple sclerosis, as well as important comorbidities to prevent infection risks. Show reference: https://www.neurology.org/doi/10.1212/NXI.0 ...  Show more

Drs. Justin Abbatemarco and Géraldine Androdias discuss the impact of immune checkpoint inhibitors on the course of multiple sclerosis.  Show reference:  https://www.neurology.org/doi/10.1212/NXI.0000000000200202   This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for ...  Show more

Dr. Justin Abbatemarco and Dr. Aaron Zelikovich discuss the safety and efficacy of satralizumab and its role in the current treatment landscape for myasthenia gravis. Show reference: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00514-3/fulltext 

We get to the bottom of a medical mystery – what causes multiple sclerosis? A series of studies have compellingly pointed the finger at the virus behind glandular fever. We see if they stack up and assess what it means for the future of preventing and treating MS. Then nearly two ...  Show more